title: Incidence and predictors of target vessel revascularization after sirolimus-eluting stent treatment for proximal left anterior descending artery stenoses among 2274 patients from the prospective multicenter German Cypher Stent Registry.
abstract: BACKGROUND
  Involvement of the proximal LAD is considered an indication for coronary artery bypass graft (CABG) surgery due to the high restenosis rates associated with this location after percutaneous coronary interventions (PCI). This seems to be different, however, when using sirolimus-eluting stents, a finding if proven to be true could have a major impact on clinical decision making regarding the optimal revascularization strategy for these patients.
  
  
  METHODS
  We analyzed 2274 patients treated for proximal LAD stenoses using SES from the German Cypher Stent Registry. The incidence of TVR and other major clinical adverse events were determined and independent predictors of TVR were specified using a multiple logistic regression model.
  
  
  RESULTS
  Event-free survival was achieved in 89.5% of patients. TVR was performed in 179 patients (7.9%) and the combined incidence of all cause death, myocardial infarction and TVR was 10.5% (231 patients). Independent predictors of TVR were multivessel disease (OR 1.74, 95% CI 1.16-2.62, p = 0.008), stent diameter < or = 2.75 mm (OR 1.61, 95% CI 1.10-2.40, p = 0.02) and the administration of GP IIb/ IIIa antagonists (OR 1.60, 95% CI 1.05-2.60, p = 0.03). TVR rate was as high as 11.2% for 2.5 mm SES and as low as 4.0% for 3.5 mm SES (p < 0.001 for trend test).
  
  
  CONCLUSIONS
  TVR among patients treated with SES for proximal LAD stenoses is low and is related in part to operator dependent factors. Treatment with SES should be considered as an effective treatment for these patients.
authors.affiliation: Herz-Kreislauf-Zentrum, Segeberger Kliniken GmbH, Am Kurpark 1, 23795, Bad Segeberg, Germany. ahmed.khattab@segebergerkliniken.de
authors.forename: Ahmed A
authors.initials: AA
authors.lastname: Khattab
authors.forename: Christian W
authors.initials: CW
authors.lastname: Hamm
authors.forename: Jochen
authors.initials: J
authors.lastname: Senges
authors.forename: Ralph
authors.initials: R
authors.lastname: Toelg
authors.forename: Volker
authors.initials: V
authors.lastname: Geist
authors.forename: Tassilo
authors.initials: T
authors.lastname: Bonzel
authors.forename: Malte
authors.initials: M
authors.lastname: Kelm
authors.forename: Benny
authors.initials: B
authors.lastname: Levenson
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Nienaber
authors.forename: Georg
authors.initials: G
authors.lastname: Sabin
authors.forename: Ulrich
authors.initials: U
authors.lastname: Tebbe
authors.forename: Steffen
authors.initials: S
authors.lastname: Schneider
authors.forename: Gert
authors.initials: G
authors.lastname: Richardt
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000150:complications / Q000601:surgery* / Q000628:therapy; D023921:Coronary Stenosis / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020123:Sirolimus; D015607:Stents; D016896:Treatment Outcome
chemical_list: D020123:Sirolimus